

WEST Search History

DATE: Friday, December 13, 2002

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ</i>			
L29	L9 and L11	0	L29
L28	L9 and L10	0	L28
L27	L8 and L11	0	L27
L26	L8 and L10	0	L26
L25	L7 and L11	0	L25
L24	L7 and L10	0	L24
L23	L6 and L11	7	L23
L22	L6 and L10	10	L22
L21	L5 and L11	3	L21
L20	L5 and L10	4	L20
L19	L4 and L11	0	L19
L18	L4 and L10	10	L18
L17	L3 and L11	2	L17
L16	L3 and L10	2	L16
L15	L2 and L11	2	L15
L14	L2 and L10	2	L14
L13	L1 and L11	21	L13
L12	L1 and L10	23	L12
L11	ribozym\$3	9004	L11
L10	antisen\$3	26528	L10
L9	CCL20	3	L9
L8	CC Chemokine Ligand 20	0	L8
L7	lover and activation regulated kinase	0	L7
L6	EXODUS 1	15	L6
L5	SCYA20	5	L5
L4	member 20	69110	L4
L3	small inducible cytokine subfamily A	10	L3
L2	MIP3A	4	L2
L1	macrophage inflammatory protein 3 alpha	25	L1

END OF SEARCH HISTORY

FILE 'BIOSIS, MEDLINE, CAPLUS, EMBASE' ENTERED AT 14:25:48 ON 13 DEC 2002

L1 363 MACROPHAGE INFLAMMATORY PROTEIN 3
L2 2834709 ALPHA
L3 296 L1 AND L2
L4 3 MIP3A
L5 12 SMALL INDUCIBLE CYTOKINE SUB
L6 138 MEMBER 20
L7 18 SCYA20
L8 47 EXODUS 1
L9 0 LIVER AND ACTIVATION REGULATED KINASE
L10 794 LARC
L11 0 LIVER AND ACTIVATION-REGULATED KINASE
L12 8 CC CHEMOKINE LIGAND 20
L13 133 CCL20
L14 77576 ANTISENS?
L15 15305 RIBOZYM?
L16 6 L3 AND L14
L17 6 DUP REM L16 (0 DUPLICATES REMOVED)
L18 3 L3 AND L15
L19 3 DUP REM L18 (0 DUPLICATES REMOVED)
L20 0 L4 AND L14
L21 0 L4 AND L15
L22 0 L5 AND L14
L23 0 L5 AND L15
L24 0 L6 AND L14
L25 0 L6 AND L15
L26 0 L7 AND L14
L27 0 L7 AND L15
L28 0 L8 AND L14
L29 0 L8 AND L15
L30 0 L9 AND L14
L31 0 L9 AND L15
L32 1 L10 AND L14
L33 0 L10 AND L15
L34 0 L11 AND L14
L35 0 L11 AND L15
L36 0 L12 AND L14
L37 0 L12 AND L15
L38 0 L13 AND L14
L39 0 L13 AND L15
L40 231 MACROPHAGE INFLAMMATORY PROTEIN 3 ALPHA
L41 3 L40 AND L14

ACCESSION NUMBER: 2002:832576 CAPLUS

DOCUMENT NUMBER: 137:346197

TITLE: Treatment of respiratory and lung diseases with
antisense oligonucleotides and a
bronchodilating agentINVENTOR(S): Nyce, Jonathan W.; Li, Yukui; Sandrasagra, Anthony;
Katz, Evan; Pabalan, Jonathan; Aguilar, Douglas;
Miller, Shoreh; Tang, Lei; Shahabuddin, Syed

PATENT ASSIGNEE(S): Epigenesis Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 764 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085309	A2	20021031	WO 2002-US13143	20020423
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2001-286036P P 20010424

AB This patent relates to a compn. comprising a carrier, oligonucleotides (oligos) that are **antisense** to adenosine receptors, and contain low amts. of or no adenosine (A), plus bronchodilating agents. All **antisense** oligonucleotides designed in accordance with the invention were highly effective at countering or reducing effects mediated by the receptors to which they are targeted. Two **antisense** phosphorothioated oligos targeting human adenosine A1 receptor mRNA, one targeting adenosine A2b receptor, and two targeting an A3 receptor are capable of countering the effect of exogenously administered adenosine which is mediated by the specific receptor they are targeted to. The activity of the **antisense** oligos are specific to the target and substitutively fail to inhibit another target. An oligonucleotide wherein the phosphodiester bonds are substituted with phosphorothioate bonds evidenced an unexpected superiority over the phosphodiester **antisense** oligo. In addn., they result in extremely low or non-existent deleterious side effects or toxicity. This represents 100% success in providing agents that are highly effective and specific in the treatment of bronchoconstriction and/or inflammation. These agents and the compn. and formulations provided are suitable for the treatment of respiratory tract, pulmonary and malignant diseases assocd. with bronchoconstriction, respiratory tract inflammation and allergies, impaired airways, including lung disease and diseases whose secondary effects afflict the lungs of a subject, such as allergies, asthma, impeded respiration, allergic rhinitis, pain, cystic fibrosis, pulmonary fibrosis, RDA, COPD, and cancers, among others. The present agents and compn. may be administered preventatively, prophylactically or therapeutically in conjunction with other therapies, or may be utilized as a substitute for therapies that have significant, neg. side effects. The method of the present invention is also practiced with **antisense** oligonucleotides targeted to many genes, mRNAs and their corresponding proteins in essential the same manner.

ACCESSION NUMBER: 2002:832575 CAPLUS
 DOCUMENT NUMBER: 137:346196
 TITLE: Treatment of respiratory and lung diseases with
 antisense oligonucleotides and a
 bronchodilating agent
 INVENTOR(S): Nyce, Jonathan W.; Li, Yukui; Sandrasagra, Anthony;
 Katz, Evan; Pabalan, Jonathan; Aguilar, Douglas;
 Miller, Shoreh; Tang, Lei; Shahabuddin, Syed
 PATENT ASSIGNEE(S): Epigenesis Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 872 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085308	A2	20021031	WO 2002-US13135	20020423
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2002085308	A2	20021031	WO 2002-XA13135	20020423
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2002085308	A2	20021031	WO 2002-XB13135	20020423
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2002085308	A2	20021031	WO 2002-XC13135	20020423
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2001-286137P P 20010424
 WO 2002-US13135 A 20020423

AB This patent relates to a compn. comprising a carrier, oligonucleotides (oligos) that are **antisense** to adenosine receptors, and contain low amts. of or no adenosine (A), plus bronchodilating agents. All **antisense** oligonucleotides designed in accordance with the invention were highly effective at countering or reducing effects mediated by the receptors to which they are targeted. Two **antisense** phosphorothioated oligos targeting human adenosine A1 receptor mRNA, one targeting adenosine A2b receptor, and two targeting an A3 receptor are capable of countering the effect of exogenously administered adenosine which is mediated by the specific receptor they are targeted to. The activity of the **antisense** oligos are specific to the target and substitutively fail to inhibit another target. An oligonucleotide wherein the phosphodiester bonds are substituted with phosphorothioate bonds evidenced an unexpected superiority over the phosphodiester **antisense** oligo. In addn., they result in extremely low or non-existent deleterious side effects or toxicity. This represents 100% success in providing agents that are highly effective and specific in the treatment of bronchoconstriction and/or inflammation. Treatment with **antisense** oligonucleotides in combination with anti-inflammatory steroid and/or ubiquinones is also provided. These agents and the compn. and formulations provided are suitable for the treatment of respiratory tract, pulmonary and malignant diseases assocd. with bronchoconstriction, respiratory tract inflammation and allergies, impaired airways, including lung disease and diseases whose secondary effects afflict the lungs of a subject, such as allergies, asthma, impeded respiration, allergic rhinitis, pain, cystic fibrosis, pulmonary fibrosis, RDA, COPD, and cancers, among others. The present agents and compn. may be administered preventatively, prophylactically or therapeutically in conjunction with other therapies, or may be utilized as a substitute for therapies that have significant, neg. side effects. The method of the present invention is also practiced with **antisense** oligonucleotides targeted to many genes, mRNAs and their corresponding proteins in essentially the same manner.

L17 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:314789 CAPLUS

DOCUMENT NUMBER: 136:339492

TITLE: LARC or LARC receptor antagonists for treatment of rheumatoid arthritis

INVENTOR(S): Nakayama, Yasunori; Kamimura, Takashi; Akahoshi, Tohru; Kondo, Hirobumi

PATENT ASSIGNEE(S): Teijin Ltd., Japan

SOURCE: PCT Int. Appl., 80 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032456	A1	20020425	WO 2001-JP3504	20010424
W: CA, US				
JP 2002187856	A2	20020705	JP 2001-315130	20011012

PRIORITY APPLN. INFO.: JP 2000-313459 A 20001013

AB Provided are remedies or preventives for rheumatoid arthritis which contain as the active ingredient a substance inhibiting LARC or a substance inhibiting LARC receptor (CCR6). The LARC or LARC receptor inhibiting substances include LARC or LARC receptor antagonists such as anti-LARC or anti-LARC receptor antibodies and neutralizing antibodies, LARC gene **antisense** DNA, LARC or LARC receptor mutants, and others.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:184856 CAPLUS

DOCUMENT NUMBER: 136:246373

TITLE: Genetically engineered co-expression DNA vaccines:
construction and application

INVENTOR(S): Hone, David; Lewis, George; Fouts, Timothy; Bagley,
Ken; Boyson, Michael; Obriecht, Christine; Shata, M.
T.; Agwale, Simon

PATENT ASSIGNEE(S): University of Maryland Biotechnology Institute, USA

SOURCE: PCT Int. Appl., 107 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002019968	A2	20020314	WO 2001-US28365	20010910
WO 2002019968	A3	20020516		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2001092610 A5 20020322 AU 2001-92610 20010910

PRIORITY APPLN. INFO.:

US 2000-231070P P 20000908
US 2000-231376P P 20000908
US 2000-231403P P 20000908
US 2000-231449P P 20000908
WO 2001-US28365 W 20010910

AB The authors disclose the prepn. and application of DNA vaccines
co-expressing antigen and a regulatory mol. for inducing a protective
immune response in animals against viral, bacterial and parasitic
pathogens. The regulatory mols. can comprise biol.-active components,
such as adjuvants, immunoregulatory agents, **antisense** RNAs,
and/or catalytic RNAs. In one example, the antibody and T-cell response
to human immunodeficiency virus gp120 was enhanced by immunization with
plasmid vector coexpressing an A chain fragment of cholera toxin.

L17 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:677067 CAPLUS

DOCUMENT NUMBER: 135:251931

TITLE: Function homology screening method, and use in
identification of drug candidates

INVENTOR(S): Berg, Ellen L.; Butcher, Eugene C.; Melrose, Jennifer;
Plavec, Ivan

PATENT ASSIGNEE(S): Bioseek, Inc., USA

SOURCE: PCT Int. Appl., 128 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001067103	A1	20010913	WO 2001-US7190	20010306

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
 HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
 LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
 RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
 VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-186976P P 20000306
 US 2000-195672P P 20000407

AB A method is provided for screening biol. active agents based on the anal.
 of complex biol. responses in culture. Methods for selecting cells and
 culture conditions for such screens are provided, as well as the
 identification of an optimized set of discrete parameters to be measured,
 and the use of biomap anal. for rapid identification and characterization
 of drug candidates, genetic sequences acting pathways, and the like. A
 feature of the invention is simultaneous screening of a large no. of
 cellular pathways, and the rapid identification of compds. that cause
 cellular responses.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:735387 CAPLUS

DOCUMENT NUMBER: 135:294008

TITLE: Antibody-coated adsorbents, column system having the
 adsorbents for hemodialysis or plasmapheresis, and
 therapy using the system

INVENTOR(S): Dunzendorfer, Udo

PATENT ASSIGNEE(S): Germany

SOURCE: Jpn. Kokai Tokkyo Koho, 31 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001276217	A2	20011009	JP 2000-102606	20000404

AB The adsorbents, useful for removing pathogenic factors from plasma or
 tissues, are coated with antibodies to TNF, TNF metabolites, TNF transport
 proteins, or TNF fragments. The adsorbents may be addnl. coated with
 monoclonal or polyclonal antibodies to pathogenic factors such as cold
 agglutinins, HLA antigens, hepatitis virus antigens, .beta.2-
 microglobulins, bacterial toxins, etc. A column system having the
 adsorbents and clin. use of the system are also claimed. Selective
 removal of these pathogens, antigens, proteins, etc. leaves all normal
 plasma components unchanged and obviates the need for supplementation of
 the plasma with these components. Suitable substrates include polymers,
 polymer-coated metals, glass, cellulose, agar, Sepharose, etc. Thus,
 dextran sulfate-induced colitis was successfully treated by plasmapheresis
 coupled with adsorbents coated with anti-TNF-.alpha. antibody.
 Addnl. coating of the adsorbents with anti-protein A antibody enhances the
 effect.

L19 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:832576 CAPLUS

DOCUMENT NUMBER: 137:346197

TITLE: Treatment of respiratory and lung diseases with antisense oligonucleotides and a bronchodilating agent

INVENTOR(S): Nyce, Jonathan W.; Li, Yukui; Sandrasagra, Anthony; Katz, Evan; Pabalan, Jonathan; Aguilar, Douglas; Miller, Shoreh; Tang, Lei; Shahabuddin, Syed

PATENT ASSIGNEE(S): Epigenesis Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 764 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085309	A2	20021031	WO 2002-US13143	20020423
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2001-286036P P 20010424

AB This patent relates to a compn. comprising a carrier, oligonucleotides (oligos) that are antisense to adenosine receptors, and contain low amts. of or no adenosine (A), plus bronchodilating agents. All antisense oligonucleotides designed in accordance with the invention were highly effective at countering or reducing effects mediated by the receptors to which they are targeted. Two antisense phosphorothioated oligos targeting human adenosine A1 receptor mRNA, one targeting adenosine A2b receptor, and two targeting an A3 receptor are capable of countering the effect of exogenously administered adenosine which is mediated by the specific receptor they are targeted to. The activity of the antisense oligos are specific to the target and substitutively fail to inhibit another target. An oligonucleotide wherein the phosphodiester bonds are substituted with phosphorothioate bonds evidenced an unexpected superiority over the phosphodiester antisense oligo. In addn., they result in extremely low or non-existent deleterious side effects or toxicity. This represents 100% success in providing agents that are highly effective and specific in the treatment of bronchoconstriction and/or inflammation. These agents and the compn. and formulations provided are suitable for the treatment of respiratory tract, pulmonary and malignant diseases assocd. with bronchoconstriction, respiratory tract inflammation and allergies, impaired airways, including lung disease and diseases whose secondary effects afflict the lungs of a subject, such as allergies, asthma, impeded respiration, allergic rhinitis, pain, cystic fibrosis, pulmonary fibrosis, RDA, COPD, and cancers, among others. The present agents and compn. may be administered preventatively, prophylactically or therapeutically in conjunction with other therapies, or may be utilized as a substitute for therapies that have significant, neg. side effects. The method of the present invention is also practiced with antisense oligonucleotides targeted to many genes, mRNAs and their corresponding proteins in essential the same manner.

L19 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:832575 CAPLUS

DOCUMENT NUMBER: 137:346196

TITLE: Treatment of respiratory and lung diseases with antisense oligonucleotides and a bronchodilating agent
 INVENTOR(S): Nyce, Jonathan W.; Li, Yukui; Sandrasagra, Anthony; Katz, Evan; Pabalan, Jonathan; Aguilar, Douglas; Miller, Shoreh; Tang, Lei; Shahabuddin, Syed
 PATENT ASSIGNEE(S): Epigenesis Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 872 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085308	A2	20021031	WO 2002-US13135	20020423
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2002085308	A2	20021031	WO 2002-XA13135	20020423
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2002085308	A2	20021031	WO 2002-XB13135	20020423
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2002085308	A2	20021031	WO 2002-XC13135	20020423
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:

US 2001-286137P P 20010424
 WO 2002-US13135 A 20020423

AB This patent relates to a compn. comprising a carrier, oligonucleotides (oligos) that are antisense to adenosine receptors, and contain low amts. of or no adenosine (A), plus bronchodilating agents. All antisense

oligonucleotides designed in accordance with the invention were highly effective at countering or reducing effects mediated by the receptors to which they are targeted. Two antisense phosphorothioated oligos targeting human adenosine A1 receptor mRNA, one targeting adenosine A2b receptor, and two targeting an A3 receptor are capable of countering the effect of exogenously administered adenosine which is mediated by the specific receptor they are targeted to. The activity of the antisense oligos are specific to the target and substitutively fail to inhibit another target. An oligonucleotide wherein the phosphodiester bonds are substituted with phosphorothioate bonds evidenced an unexpected superiority over the phosphodiester antisense oligo. In addn., they result in extremely low or non-existent deleterious side effects or toxicity. This represents 100% success in providing agents that are highly effective and specific in the treatment of bronchoconstriction and/or inflammation. Treatment with antisense oligonucleotides in combination with anti-inflammatory steroid and/or ubiquinones is also provided. These agents and the compn. and formulations provided are suitable for the treatment of respiratory tract, pulmonary and malignant diseases assocd. with bronchoconstriction, respiratory tract inflammation and allergies, impaired airways, including lung disease and diseases whose secondary effects afflict the lungs of a subject, such as allergies, asthma, impeded respiration, allergic rhinitis, pain, cystic fibrosis, pulmonary fibrosis, RDA, COPD, and cancers, among others. The present agents and compn. may be administered preventatively, prophylactically or therapeutically in conjunction with other therapies, or may be utilized as a substitute for therapies that have significant, neg. side effects. The method of the present invention is also practiced with antisense oligonucleotides targeted to many genes, mRNAs and their corresponding proteins in essential the same manner.

L19 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:184856 CAPLUS

DOCUMENT NUMBER: 136:246373

TITLE: Genetically engineered co-expression DNA vaccines: construction and application

INVENTOR(S): Hone, David; Lewis, George; Fouts, Timothy; Bagley, Ken; Boyson, Michael; Obriecht, Christine; Shata, M. T.; Agwale, Simon

PATENT ASSIGNEE(S): University of Maryland Biotechnology Institute, USA

SOURCE: PCT Int. Appl., 107 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002019968	A2	20020314	WO 2001-US28365	20010910
WO 2002019968	A3	20020516		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2001092610	A5	20020322	AU 2001-92610	20010910
PRIORITY APPLN. INFO.:			US 2000-231070P	P 20000908
			US 2000-231376P	P 20000908
			US 2000-231403P	P 20000908
			US 2000-231449P	P 20000908
			WO 2001-US28365	W 20010910

AB The authors disclose the prepn. and application of DNA vaccines co-expressing antigen and a regulatory mol. for inducing a protective immune response in animals against viral, bacterial and parasitic pathogens. The regulatory mols. can comprise biol.-active components, such as adjuvants, immunoregulatory agents, antisense RNAs, and/or catalytic RNAs. In one example, the antibody and T-cell response to human immunodeficiency virus gp120 was enhanced by immunization with plasmid vector coexpressing an A chain fragment of cholera toxin.

=>

L32 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:314789 CAPLUS

DOCUMENT NUMBER: 136:339492

TITLE: **LARC** or **LARC** receptor antagonists
for treatment of rheumatoid arthritis

INVENTOR(S): Nakayama, Yasunori; Kamimura, Takashi; Akahoshi,
Tohru; Kondo, Hirobumi

PATENT ASSIGNEE(S): Teijin Ltd., Japan

SOURCE: PCT Int. Appl., 80 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2002032456	A1	20020425	WO 2001-JP3504	20010424
W: CA, US				
JP 2002187856	A2	20020705	JP 2001-315130	20011012
PRIORITY APPLN. INFO.:			JP 2000-313459	A 200001013

AB Provided are remedies or preventives for rheumatoid arthritis which contain as the active ingredient a substance inhibiting **LARC** or a substance inhibiting **LARC** receptor (CCR6). The **LARC** or **LARC** receptor inhibiting substances include **LARC** or **LARC** receptor antagonists such as anti-**LARC** or anti-**LARC** receptor antibodies and neutralizing antibodies, **LARC** gene **antisense** DNA, **LARC** or **LARC** receptor mutants, and others.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2002:314789 CAPLUS
 DOCUMENT NUMBER: 136:339492
 TITLE: LARC or LARC receptor antagonists for treatment of
 rheumatoid arthritis
 INVENTOR(S): Nakayama, Yasunori; Kamimura, Takashi; Akahoshi,
 Tohru; Kondo, Hirobumi
 PATENT ASSIGNEE(S): Teijin Ltd., Japan
 SOURCE: PCT Int. Appl., 80 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032456	A1	20020425	WO 2001-JP3504	20010424
W: CA, US				
JP 2002187856	A2	20020705	JP 2001-315130	20011012
PRIORITY APPLN. INFO.:			JP 2000-313459 A	200001013
AB Provided are remedies or preventives for rheumatoid arthritis which contain as the active ingredient a substance inhibiting LARC or a substance inhibiting LARC receptor (CCR6). The LARC or LARC receptor inhibiting substances include LARC or LARC receptor antagonists such as anti-LARC or anti-LARC receptor antibodies and neutralizing antibodies, LARC gene antisense DNA, LARC or LARC receptor mutants, and others.				
REFERENCE COUNT:	7	THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L41 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2002:184856 CAPLUS
 DOCUMENT NUMBER: 136:246373
 TITLE: Genetically engineered co-expression DNA vaccines:
 construction and application
 INVENTOR(S): Hone, David; Lewis, George; Fouts, Timothy; Bagley,
 Ken; Boyson, Michael; Obriecht, Christine; Shata, M.
 T.; Agwale, Simon
 PATENT ASSIGNEE(S): University of Maryland Biotechnology Institute, USA
 SOURCE: PCT Int. Appl., 107 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002019968	A2	20020314	WO 2001-US28365	20010910
WO 2002019968	A3	20020516		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001092610	A5	20020322	AU 2001-92610	20010910
PRIORITY APPLN. INFO.:				
			US 2000-231070P	P 20000908
			US 2000-231376P	P 20000908
			US 2000-231403P	P 20000908

US 2000-231449P P 20000908

WO 2001-US28365 W 20010910

AB The authors disclose the prepn. and application of DNA vaccines co-expressing antigen and a regulatory mol. for inducing a protective immune response in animals against viral, bacterial and parasitic pathogens. The regulatory mols. can comprise biol.-active components, such as adjuvants, immunoregulatory agents, **antisense** RNAs, and/or catalytic RNAs. In one example, the antibody and T-cell response to human immunodeficiency virus gp120 was enhanced by immunization with plasmid vector coexpressing an A chain fragment of cholera toxin.

L41 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:677067 CAPLUS

DOCUMENT NUMBER: 135:251931

TITLE: Function homology screening method, and use in identification of drug candidates

INVENTOR(S): Berg, Ellen L.; Butcher, Eugene C.; Melrose, Jennifer; Plavec, Ivan

PATENT ASSIGNEE(S): Bioseek, Inc., USA

SOURCE: PCT Int. Appl., 128 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001067103	A1	20010913	WO 2001-US7190	20010306
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.:

US 2000-186976P P 20000306

US 2000-195672P P 20000407

AB A method is provided for screening biol. active agents based on the anal. of complex biol. responses in culture. Methods for selecting cells and culture conditions for such screens are provided, as well as the identification of an optimized set of discrete parameters to be measured, and the use of biomap anal. for rapid identification and characterization of drug candidates, genetic sequences acting pathways, and the like. A feature of the invention is simultaneous screening of a large no. of cellular pathways, and the rapid identification of compds. that cause cellular responses.

REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT